News
TECH
56.73
+2.01%
1.12
Bio-Techne named a best smid-cap idea at TD Cowen
TipRanks · 2h ago
Analyst Reiterates Buy on Bio-Techne, Sees Undervalued Shares and Margin Upside with Unchanged $65 Price Target
TipRanks · 4h ago
Incyte Corp. Stock Rises 5.5%, Outperforms Peers
Dow Jones · 17h ago
Weekly Report: what happened at TECH last week (0615-0619)?
Weekly Report · 1d ago
Is Bio-Techne Stock Underperforming the S&P 500?
Barchart · 1d ago
Notable healthcare headlines for the week: Merck, Moderna, and Biogen in focus
Seeking Alpha · 2d ago
Bio-Techne Corp. Stock Rallies 5.3%, Outperforms Peers
Dow Jones · 4d ago
U.S. RESEARCH ROUNDUP- Datadog, Jabil, Prologis
Reuters · 5d ago
Bio-Techne (TECH) Stock Could Be 10.4% Undervalued After Refeyn Collaboration
Simply Wall St · 5d ago
BIO-TECHNE CORP <TECH.O>: PIPER SANDLER CUTS TARGET PRICE TO $60 FROM $65
Reuters · 5d ago
Bio-Techne (TECH) Stock After 30% Monthly Jump Are Recent Gains Justified
Simply Wall St · 6d ago
Incyte Corp. Stock Slips 6.0%, Underperforms Peers
Dow Jones · 06/15 20:34
Bio-Techne gains on report activist investor Ananym pushing for sale
Seeking Alpha · 06/15 15:53
Activist Investor Ananym Capital Urges Bio-Techne To Explore Sale Options
NASDAQ · 06/15 13:25
ACTIVIST INVESTOR ANANYM URGES BIO-TECHNE TO CONSIDER SELLING - BLOOMBERG NEWS
Reuters · 06/15 12:45
Weekly Report: what happened at TECH last week (0608-0612)?
Weekly Report · 06/15 09:42
What Bio-Techne (TECH)'s New Refeyn Partnership Means For Shareholders
Simply Wall St · 06/11 19:29
Twist Bio favored at Piper despite wait-and-see approach for tools stocks
Seeking Alpha · 06/11 15:24
SpaceX initiated, Intel upgraded: Wall Street’s top analyst calls
TipRanks · 06/11 13:43
TD Cowen Sticks to Their Buy Rating for Bio-Techne (TECH)
TipRanks · 06/11 09:56
More
Webull provides a variety of real-time TECH stock news. You can receive the latest news about Bio-Techne Corp through multiple platforms. This information may help you make smarter investment decisions.
About TECH
Bio-Techne Corporation develop, manufacture and sell life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide. The Company’s segments include Protein Sciences segment and Diagnostics and Spatial Biology segment. The Protein Sciences segment is a developer and manufacturer of purified proteins and reagent solutions, most notably cytokines and growth factors, antibodies, immunoassays, biologically active small molecule compounds, tissue culture reagents and T-Cell activation technologies. The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products, including controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM and clinical customers. This segment also manufactures and sells fully automated multiomic spatial biology instrumentation and advanced tissue-based in-situ hybridization assays (ISH) for research and clinical use.